SEC Tracker
Get the app
NVNO · XBRL financial data

enVVeno Medical financial statements, every fiscal year

The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal years (NVNO's year ends in late December)

In thousands of dollarsDec 31, 2020Dec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024†Dec 31, 2025
Research and development4,2525,7289,91413,58312,2499,981
Selling, general and administrative4,88311,16515,01811,65511,57710,918
Operating income (loss)(9,135)(16,893)(24,932)(25,238)(23,826)(20,899)
Other income (expense)(216)33————
Net income (loss)(9,135)(16,528)(24,669)(23,516)(21,819)(19,472)
Earnings per share, basic USD per share—(1.90)(2.20)(1.91)(1.27)(33.06)
Earnings per share, diluted USD per share——(2.20)(1.91)(1.27)(33.06)
Weighted average shares, basic thousands of shares—8,68011,23012,30117,142589
Weighted average shares, diluted thousands of shares——11,23012,30117,142589
  • † Share count changed about 1/27 in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Balance sheet

CSV

Fiscal years (NVNO's year ends in late December)

In thousands of dollarsDec 31, 2020Dec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024†Dec 31, 2025
Cash and cash equivalents9,33554,7284,5553,6201,7543,065
Short-term investments——34,48942,79241,39925,147
Prepaid and other current assets234312392511581614
Total current assets9,56955,04039,43646,92343,73428,826
Property and equipment, net39961852133418251
Right-of-use asset5401,9871,6731,3471,007654
Total assets10,53857,69941,66148,63544,95429,562
Accounts payable1,390560648—1,006358
Accrued liabilities1,136—————
Total current liabilities3,1861,5801,5301,3712,0952,122
Lease liability, non-current2541,7151,4021,064700310
Total liabilities3,4403,2952,9322,4352,7952,432
Accumulated deficit(65,323)(81,851)(106,520)(130,036)(151,855)(171,327)
Total stockholders' equity7,09854,40438,72946,20042,15927,130
Total liabilities and equity10,53857,69941,66148,63544,95429,562
Common shares outstanding (cover page) thousands of shares8,5049,4709,47213,31717,536656
  • † Share count changed about 1/27 in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Cash flows

CSV

Fiscal years (NVNO's year ends in late December)

In thousands of dollarsDec 31, 2020Dec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024†Dec 31, 2025
Net income (loss)(9,135)(16,528)(24,669)(23,516)(21,819)(19,472)
Stock-based compensation6935,9998,9945,1964,1413,420
Net cash from operating activities(7,677)(11,846)(15,619)(18,858)(16,838)(15,568)
Purchases of property and equipment18036811533375
Net cash from investing activities(180)(368)(34,554)(7,868)1,33515,856
Proceeds from issuing common stock12,23457,372—25,800—782
Net cash from financing activities15,07557,607—25,79113,6371,023
Net change in cash7,21745,393(50,173)(935)(1,866)1,311
  • † Share count changed about 1/27 in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Compare with peers

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
enVVeno Medical2,585not reported(3,178)*694,8265.6 quarters 10-QSep 30, 2026
TELA Bio30,42419,291(9,381)*44.9M3.2 quarters 10-QJun 30, 2026
Apyx Medical27,61713,884(3,490)*42.1M7.9 quarters 10-QJun 30, 2026
Spectral AI14,0003,524(4,097)*32.2M3.4 quarters 10-QJun 30, 2026
Sensus Healthcare15,1862,290(3,133)*16.5M4.8 quarters 10-QJun 30, 2026
Lucid Diagnostics33,404not reported(11,297)*203.2M3.0 quarters 10-QJun 30, 2026
Pro Dex11,75920,5606,4903.2M— 10-QSep 30, 2026
Accuray40,623100,919*2,427*119.4M— 10-KJun 30, 2026
Orchestra BioMed Holdings20,47288(19,332)*60.1M5.7 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.